linjc16/ctgov huggingface dataset:
Local Anesthetic Injection Into Both Angles of the Rectus Sheath Incision

Study Overview
=================
Brief Summary
-----------------
Local anesthetic will be injected into both angles of the rectus sheath incision in an attempt to block sensory nerves in this area that cause the sensation of pain from lscs wound.

Official Title
-----------------
Efficacy of Local Anesthetic Injection Into Both Angles of the Rectus Sheath Incision for Postoperative Cesarean Delivery Analgesia.

Conditions
-----------------
Postoperative Cesarean Delivery Pain

Intervention / Treatment
-----------------
* Drug: 10ml of bupivacaine 0.5%
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients booked for lscs primisection singleton pregnancy Exclusion Criteria: emergency cesarean section bleeding tendency hypersensitivity to local anesthetic

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: bupivacaine group<br>This is the group of patients that will receive 10ml of bupivacaine 0.5% injection in both angles of the rectus sheath incision | Drug: 10ml of bupivacaine 0.5%<br>* This is a local anesthetic that will be used to block the ilioinguinal nerve to alleviate pain at the wound site after lscs<br>|
| Placebo Comparator: saline group<br>This group will receive saline injections as placebo into both angles of the rectus sheath incision | Drug: Placebo<br>* 10 ml of saline will be injected as a placebo and the investigator and the patient and the data assessor are all blinded to what the patients received.<br>* Other names: saline;|
| Experimental: bupivacaine and saline group<br>This group will receive saline injection in one angle and 10ml of bupivacaine 0.5% injection in the opposite angle. | Drug: 10ml of bupivacaine 0.5%<br>* This is a local anesthetic that will be used to block the ilioinguinal nerve to alleviate pain at the wound site after lscs<br>Drug: Placebo<br>* 10 ml of saline will be injected as a placebo and the investigator and the patient and the data assessor are all blinded to what the patients received.<br>* Other names: saline;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain assessment during rest and ambulation by visual analogue scale |  | for 24 hours after lscs |
Factor VIIa in Acute Intracerebral Haemorrhage

Study Overview
=================
Brief Summary
-----------------
This trial is conducted in Japan. The purpose of this trial is to evaluate the safety and preliminary efficacy of Activated Recombinant Factor VII (NN-007) in patients with acute intracerebral haemorrhage.

Official Title
-----------------
Safety of Eptacog Alfa (Activated) (Genetical Recombination) on Adverse Events and Serious Adverse Events in Patients With Acute Intracerebral Haemorrhage.

Conditions
-----------------
Acquired Bleeding Disorder, Intracerebral Haemorrhage

Intervention / Treatment
-----------------
* Drug: eptacog alfa (activated)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Spontaneous ICH Exclusion Criteria: Time of ICH onset > 3 hours Patients with secondary ICH Pre-existing disability Hemophilia

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: eptacog alfa (activated)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Occurrence of thromboembolic serious adverse event |  | Until 90 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reducing disability and improving clinical outcome |  |  | 
| Reducing haematoma growth |  |  |
Clinical Trial of Autologous Adipose Tissue Derived Stromal Cell Therapy for Ischemic Heart Failure

Study Overview
=================
Brief Summary
-----------------
Mesenchymal stem cells have capability to differentiate into myocardium, vascular endothelial cell, vascular smooth muscle cell and will be useful for heart regeneration. Adipose tissue is relatively enriched with mesenchymal stem cell compared to bone marrow tissue. In this trial, eligible ischemic heart failure patients will be proceeded intracoronary administration of autologous adipose tissue derived stromal cells by cardiac catheterization.

Detailed Description
-----------------
The population of the ischemic heart failure patients is enormous in Japan and the only radical treatment for them is heart transplantation: however, the number of giving donor is extremely limited. Mesenchymal stem cells have been capable to differentiate into mesodermal-lineage cells as well as endodermal-lineage cells such as myocardial cell. They reside in the mesenchymal tissues such as bone marrows as well as adipose tissues. The latter tissues are relatively enriched with mesenchymal stem cells compared to bone marrow cells. In this study, the ischemic heart failure patients will undergo intracoronary administration of autologous adipose tissue derived stromal cells through cardiac catheterization.

Conditions
-----------------
Ischemic Heart Failure

Intervention / Treatment
-----------------
* Biological: adipose tissue derived stromal cells dosage


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Heart failure patients occured by prior ischemic event whose ejection fraction must be less than 40%. Exclusion Criteria: Complicated severe other organ disease. Patient with malignancy. History of chemotherapy or irradiation within 4 weeks. Patient with immunodeficiency Pregnancy or possibility of pregnancy Candidate who are judged to be not applicable to this study by doctors.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: adipose tissue derived stromal cells<br> | Biological: adipose tissue derived stromal cells dosage<br>* intra-coronary administration of autologous adipose tissue derived stroma cells<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| all cause harmful events |  | 6 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ischemic heart failure, Myocardial regeneration, ADRC
Association Between Cortisol, Cortisone, Cotinine, Nicotine, Caffeine, Melatonin Levels in Hair, Serum, Urine, Saliva and Chronic Stress

Study Overview
=================
Brief Summary
-----------------
The investigators aim to investigate the association between hair, serum, urine and saliva to measure cortisol, cortisone, cotinine, nicotine, melatonin and caffeine.

Conditions
-----------------
Hydrocortisone

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult volunteer Exclusion Criteria: students of the study host people who have steroid or melatonin medicine

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Chinese Health Questionnaire (CHQ) |  | 5 minutes | 
| Hospital Anxiety and Depression Scale (HADS) |  | 5 minutes | 
| Pittsburgh Sleep Quality Index (PSQI) |  | 5 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
biomarker
Imaging With 11C-erlotinib PET/CT to Identify Responders to Erlotinib Treatment in NSCLC

Study Overview
=================
Brief Summary
-----------------
New treatment strategies have been developed in lung cancer targeting the Epidermal Growth Factor Receptor (EGFR). Patients with an activating mutation in the EGFR have high responds rates to the treatment and should be treated with a EGFR inhibitor as first line of treatment. Some wild type patients do as well respond but selection of these patients is more difficult. Erlotinib has been labeling with 11C and used as a new PET tracer. Accumulation of the tracer (11C-erlotinib) in tumors has showed promising results for selection of responders. The investigators now want to conduct a larger clinical study to evaluate if accumulation of tracer on a pre-treatment 11C-erlotinib PET/CT can predict responds to erlotinib.

Official Title
-----------------
Imaging With 11C-erlotinib PET/CT to Identify Responders to Erlotinib Treatment in NSCLC

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Other: 11C-erlotinib PET/CT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Lung Cancer patients with non-small cell histology and stage IV disease who are candidate for erlotinib treatment as first/ second/ third line of treatment Exclusion Criteria: pregnancy severe dyspnoea

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: NSCLC, erlotinib treatment, 11C-erlotinib PET/CT<br> | Other: 11C-erlotinib PET/CT<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accumulation of 11c-erlotinib in tumors before and after treatment with erlotinib | Accumulation of 11c-erlotinib in tumors will be correlated to PFS on erlotinib treatment. | From date of inclusion until the date of first documented progression on the erlotinib treatment or date of death, whichever came first, assessed up to 30 months |
Diastolic Dysfunction and Atrial Fibrillation in CABG Surgery

Study Overview
=================
Brief Summary
-----------------
Left ventricular (LV) diastolic dysfunction is a common manifestation of heart disease that is responsible for significant morbidity and mortality.It is present when the ventricular filling is impaired as a result of delayed relaxation or decreased compliance. During Coronary artery bypass grafting (CABG) surgery, LV diastolic dysfunction is a frequent occurrence. Failure of the left ventricle to dilate normally causes an increase in LV filling pressure. Atrial fibrillation (AF) is a common complication after cardiac surgery affecting 20-30% of patients undergoing coronary revascularization procedures. AF is associated with significant morbidity and mortality and has been identified as a causative factor of increased length of both hospital and intensive care unit (ICU) stay after CABG surgery, resulting in increased resource utilization and medical care costs.The primary aim of this study is to determine if patients with preoperative diastolic dysfunction are exposed to higher risk of AF after coronary revascularization surgery.

Official Title
-----------------
Diastolic Dysfunction and Atrial Fibrillation in Patients Undergoing Coronary Revascularization Surgery

Conditions
-----------------
Heart Disease, Atrial Fibrillation

Intervention / Treatment
-----------------
* Procedure: Diastolic measurements during TEE


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: scheduled for elective CABG or OPCAB surgery signed informed consent Exclusion Criteria: Patients with a history of previous heart surgery and/or undergoing valvular heart surgery. Patients with preoperative atrial fibrillation. Patients in whom TEE is contraindicated.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Diastolic measurements during TEE|Transesophageal echocardiography with diastolic measurements|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Is to determine if patients with preoperative diastolic dysfunction are exposed to higher risk of AF after coronary revascularization surgery. |  | pre and post operative | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Is to determine if diastolic dysfunction and AF are associated with increased perioperative cardiac morbidity and reduced event-free survival. |  | post operative until discharge | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cardiac Surgery, Diastolic Dysfunction, Atrial Fibrillation
Rapid and Highly Sensitive Detection of Fluorescently-labeled Troponin in Patients Admitted With Chest Pain

Study Overview
=================
Brief Summary
-----------------
Patients with chest pain may have postponed or missed diagnosis of acute coronary events due to relatively late detection of troponin elevation. The study will investigate a new diagnostic method for early detection of even minimal troponin elevation in patients admitted with chest pain.

Detailed Description
-----------------
Patients with chest pain may have postponed or missed diagnosis of acute coronary events due to relatively late detection of troponin elevation. The study will investigate a new diagnostic method for early detection of even minimal troponin elevation in patients admitted with chest pain. A new diagnostic method will be applicated in the recent studies.

Official Title
-----------------
Rapid and Highly Sensitive Detection of Fluorescently-labeled Troponin in Patients Admitted With Chest Pain

Conditions
-----------------
Chest Pain

Intervention / Treatment
-----------------
* Other: Blood testing in a newly described method


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients 18 years old or older Admitted to Rambam health campus for the investigation of chest pain Exclusion Criteria: 1. No exclusion criteria will be applied

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 120 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Blood testing in a newly described method|To exploit detection strategy termed Magnetic Modulation Biosensing, or MMB) to develop a novel, low-cost platform that can detect biomarkers, such as proteins and specific DNA sequences, rapidly and directly from real samples at very low concentrations.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to detect troponin elevation |  | sixty to 120 minutes |
Efficacy of Telerehabilitation in the Patients With Aphasia

Study Overview
=================
Brief Summary
-----------------
The study will invite 30 patients to join, and they will be arranged in the face to face group and telerehabilitation group randomly. In the telerehabilitation group, the investigators use the mobile device, which with the camera and speaker, for patients to practice the naming training at home, and assess the speech ability every 2-4weeks by speech therapist via telerehabilitation platform. Concise Chinese Aphasia Test (CCAT) and ASHA FACS conceptual framework Test will be used as the assessment tool for evaluation speech ability and functional ability. The investigators expect that patients can improve their speech ability, functional ability, and quality of life via telerehabilitation speech therapy. And the investigators can establish the standard telerehabilitation speech therapy protocol for aphasia therapy.

Official Title
-----------------
Efficacy of Telerehabilitation in the Patients With Aphasia

Conditions
-----------------
Aphasia

Intervention / Treatment
-----------------
* Procedure: Smart Phone Based Assistive Speech Therapeutic System
* Procedure: Mobile phone-based tele rehabilitation program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients diagnosed as aphasia Exclusion Criteria: poor auditory comprehension

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Aphasia group<br>Aphasia | Procedure: Smart Phone Based Assistive Speech Therapeutic System<br>* use the mobile device, which with the camera and speaker, for patients to practice the naming training at home, and assess the speech ability every 2-4weeks by speech therapist via telerehabilitation platform. Concise Chinese Aphasia Test (CCAT) will be used as the assessment tool for evaluation speech ability and functional ability.<br>Procedure: Mobile phone-based tele rehabilitation program<br>* Mobile phone-based tele rehabilitation program<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Concise Chinese Aphasia Test |  | monthly changes within 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
telerehabilitation, aphasia, speech therapy, rehabilitation device, visual action therapy, naming drills
CT-scan Airways Mensuration - Correlation to External Measurements

Study Overview
=================
Brief Summary
-----------------
Oro-tracheal intubation is performed daily in anesthesia and in the ICU. When a patient is intubated, the endotracheal tube must be inserted into the trachea to the right depth. If the tube is not deep Inserted enough there is a risk of accidental extubation and trauma to the vocal cords by the balloon. If the tube is inserted too far there is a risk of selective intubation into the right or left mainstem bronchus, which can lead to contralateral lung atelectasis and hypoxemia. The purpose of this study is to determine whether there is a correlation between the measurement of the airway of an adult population and criteria that would be easily accessible in daily clinical practice: the height of the patient and the size of their feet.

Conditions
-----------------
Intubation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient scheduled for a CT-scan including the airways and the upper part of the chest at least until the carina patient size between between 150 cm and 195 cm Exclusion Criteria: significant deformity of the cervical spine to accurately measure the size of patients (kyphoscoliosis...) impossibility of reliably know the size of the patient history of pharyngo-laryngeal surgery resulting in a significant deformity or a loss of anatomical landmarks incompatible with reliable measurements between dental arches and glottic plan (total laryngectomy...) history of lung surgery not allowing reliable location of the carina (pneumonectomy, double-lung transplant)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| size of the patients and/or size of their feet | measured with a height chart and/or a pedometer | Duration of the CT-scan : about 1 hour | 
| measurement of patients' airways | Mensurations of airways measured on imaging (CT-scan) | Duration of the CT-scan : about 1 hour |
Effects of Somatostatin on Liver in ADPKD

Study Overview
=================
Brief Summary
-----------------
Autosomal dominant polycystic kidney disease (ADPKD) is associated with the development of a variety of extrarenal manifestations of which polycystic liver disease is most common. The investigators aimed to assess the changes over time of liver volume in ADPKD patients and whether it is affected by the treatment with the somatostatin analogue, octreotide. 35 ADPKD patients (14 males) aged 34±8 years were randomly assigned to 36 month treatment with placebo (n=18) or octreotide (n=17). Clinical and liver parameters at magnetic resonance (RM) were evaluated at baseline, study end and after 24 months of drug withdrawal.

Official Title
-----------------
Effect of Long-acting Somatostatin on Liver in Autosomal Dominant Polycystic Kidney Disease

Conditions
-----------------
Autosomal Dominant Polycystic Kidney Disease

Intervention / Treatment
-----------------
* Drug: octeotride
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosis of autosomal dominant polycystic kidney and liver disease glomerular filtration rate greater than 40 ml/min Exclusion Criteria: diabetes mellitus proteinuria greater than 1 g/24 hours significant glomerular disease urinary tract lithiasis and infections symptomatic gallstones biliary sludge cancer pregnant women lactanting women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: OCTEOTRIDE<br>octeotride 20 mg, intramuscular injection monthly for 3 years | Drug: octeotride<br> <br> |
| Placebo Comparator: Placebo<br>Placebo (saline soluction), intramuscular injection monthly for 3 years | Drug: placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effect of somatostatin on liver volume |  | 3 years |